Skin cancer is the second most common type of cancer in the UK, with more than one in three people living with the condition.
The average age of a person with skin cancer is 58, according to the National Cancer Intelligence Service, while the average life expectancy for people diagnosed with the disease is less than 10 years.
But the majority of skin cancers are very rarely fatal, meaning they are treatable with the right treatment and the right treatments can help reduce the risk of dying from the disease.
There are two main types of skin cancer: basal cell and non-basal cell.
Basma cell is the most common and most common skin cancer, which is caused by cells in the outer layer of the skin called the epidermis, which are made up of keratin, a protein found in our hair and nails.
It is estimated that there are between 6 and 7 million basal cell cancers in the world, according the World Health Organisation.
People living with basal cell cancer tend to have a slightly higher risk of developing skin cancer and melanoma, the most serious form of skin disease.
However, the risk for melanoma is increased by a factor of more than 20, according Healthline.
Researchers at the University of Warwick said basal cell skin cancer was the most aggressive type of skin cell cancer and had a 50 per cent increase in risk of death over the 20 years the study was undertaken.
They compared the risk between people who had basal cell disease and people who did not, and found the incidence of melanoma increased by 23 per cent.
The study also found the skin cancer risk increased for people with both basal cell, non-basma cell, and non melanoma skin cancers.
Researchers also found there were significant differences between women and men with skin cancers, with women having a higher risk than men.
People with basal and non basal cell types of cancer are at increased risk of skin and eye cancers, according a report by the National Health Service.
“Basma cells are very active, and therefore, in people with skin or eye cancers there is a heightened risk of melanomas,” Dr Helen Lewis, from the University’s Department of Medical Pathology, told the BBC.
“There are a number of different types of melanosarcoma, which include basal cell melanoma and nonbasma melanoma.”
If you have melanoma then basal cells are the cells that are most active, but it is important that you have these cells removed as early as possible.
“Non melanoma melanoma has a different pattern, and they may have the greatest risk.”
People with melanoma have a higher rate of melano-epidermal neoplasia than those with basal cells, but that is because melanoma cells are more aggressive.
“The University of Reading said skin cancer rates were higher for women, but there were no significant differences in risk.
The National Cancer Institute said there were more than 10 million skin cancers in England and Wales, of which basal cell has been identified as the most prevalent.”
Skin cancer is one of the leading causes of cancer deaths worldwide, and is the leading cause of death for young women in England,” said NCA’s chief executive officer, Stephen Brown, in a statement.”
Our work to reduce the cancer risk of people living in the country and protect them from the harms of skin-related disease will continue.
“There are also differences in how the different types differ in their effect on people.
For example, the melanoma type is more common in people of lighter skin, and less common in darker skin.”
The skin type and the degree of basal cell [skin] cancer are also linked to risk of cancer of the brain and lung,” the NCA said.”
These differences in skin type are also important when considering whether melanoma will affect your ability to fight it.””
These findings show that the overall impact of basal cells on the risk and survival of skin types and skin cancer are different for men and women.
“The NCA also said there was “strong evidence” that basal cells increase the risk or survival of some types of cancers, such as melanoma or squamous cell carcinoma.
But researchers said there is currently no standardised way to identify the type of basal skin cancer that someone has.”
We are still trying to find the most accurate measure of basal-cell skin cancer,” Dr Lewis said.